<DOC>
	<DOCNO>NCT00657904</DOCNO>
	<brief_summary>The purpose trial study effect - term time progression overall survival - 2 year adjuvant bicalutamide 150mg monotherapy , versus placebo , subject histologically cytologically confirm non-metastatic adenocarcinoma prostate gland .</brief_summary>
	<brief_title>Bicalutamide ( Casodexâ„¢ ) Versus Placebo Patients With Early Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Prostate cancer early stage disease Prostate remove and/or radiation therapy prostate area Previous systemic therapy prostate cancer Previous history another form cancer ( prostate ) within 5 year study start .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>androgen antagonist</keyword>
	<keyword>prostate neoplasm</keyword>
</DOC>